WuXi Biologics (Cayman) Gelecekteki Büyüme
Future kriter kontrolleri 3/6
WuXi Biologics (Cayman) is forecast to grow earnings and revenue by 18.3% and 10.7% per annum respectively. EPS is expected to grow by 17% per annum. Return on equity is forecast to be 9% in 3 years.
Anahtar bilgiler
18.3%
Kazanç büyüme oranı
17.0%
EPS büyüme oranı
| Life Sciences kazanç büyümesi | 50.3% |
| Gelir büyüme oranı | 10.7% |
| Gelecekteki özkaynak getirisi | 9.0% |
| Analist kapsamı | Good |
| Son güncelleme | 28 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 22,949 | 4,738 | 2,269 | 7,200 | 27 |
| 12/31/2025 | 20,186 | 3,980 | 1,065 | 6,204 | 29 |
| 12/31/2024 | 17,881 | 3,282 | 817 | 6,004 | 28 |
| 6/30/2024 | 17,116 | 2,632 | -322 | 3,220 | N/A |
| 3/31/2024 | 17,075 | 3,016 | 145 | 3,944 | N/A |
| 12/31/2023 | 17,034 | 3,400 | 612 | 4,668 | N/A |
| 9/30/2023 | 16,794 | 3,776 | N/A | N/A | N/A |
| 6/30/2023 | 16,554 | 4,152 | 1,269 | 6,834 | N/A |
| 3/31/2023 | 15,911 | 4,286 | 471 | 6,188 | N/A |
| 12/31/2022 | 15,269 | 4,420 | -327 | 5,542 | N/A |
| 9/30/2022 | 14,179 | 4,251 | N/A | N/A | N/A |
| 6/30/2022 | 13,090 | 4,081 | -1,028 | 4,091 | N/A |
| 3/31/2022 | 11,690 | 3,735 | -2,052 | 3,761 | N/A |
| 12/31/2021 | 10,290 | 3,388 | -3,077 | 3,431 | N/A |
| 9/30/2021 | 9,183 | 3,092 | -4,006 | 2,840 | N/A |
| 6/30/2021 | 8,075 | 2,795 | -4,936 | 2,249 | N/A |
| 3/31/2021 | 6,844 | 2,242 | -4,540 | 2,065 | N/A |
| 12/31/2020 | 5,612 | 1,689 | -4,144 | 1,881 | N/A |
| 9/30/2020 | 4,967 | 1,494 | -4,049 | 1,649 | N/A |
| 6/30/2020 | 4,321 | 1,300 | -3,954 | 1,417 | N/A |
| 3/31/2020 | 4,152 | 1,157 | -2,979 | 1,312 | N/A |
| 12/31/2019 | 3,984 | 1,014 | -2,004 | 1,208 | N/A |
| 9/30/2019 | 3,535 | 922 | -1,356 | 1,035 | N/A |
| 6/30/2019 | 3,087 | 831 | -708 | 861 | N/A |
| 3/31/2019 | 2,811 | 731 | -810 | 811 | N/A |
| 12/31/2018 | 2,534 | 631 | -912 | 762 | N/A |
| 9/30/2018 | 2,277 | 520 | -1,004 | 508 | N/A |
| 6/30/2018 | 2,019 | 410 | -1,096 | 255 | N/A |
| 3/31/2018 | 1,819 | 331 | N/A | 308 | N/A |
| 12/31/2017 | 1,619 | 253 | N/A | 360 | N/A |
| 9/30/2017 | 1,429 | 177 | N/A | 320 | N/A |
| 6/30/2017 | 1,233 | 149 | N/A | 369 | N/A |
| 3/31/2017 | 1,111 | 145 | N/A | 226 | N/A |
| 12/31/2016 | 989 | 141 | N/A | 82 | N/A |
| 9/30/2016 | 889 | 171 | N/A | 162 | N/A |
| 12/31/2015 | 557 | 45 | N/A | 107 | N/A |
| 12/31/2014 | 332 | 42 | N/A | 22 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 2269's forecast earnings growth (18.3% per year) is above the savings rate (2.3%).
Kazançlar ve Piyasa: 2269's earnings (18.3% per year) are forecast to grow faster than the Hong Kong market (11.5% per year).
Yüksek Büyüme Kazançları: 2269's earnings are forecast to grow, but not significantly.
Gelir ve Pazar: 2269's revenue (10.7% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).
Yüksek Büyüme Geliri: 2269's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 2269's Return on Equity is forecast to be low in 3 years time (9%).